Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06557460 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
A Phase 2 study of Geographic Atrophy and Dry Age-Related Macular Degeneration, sponsored by Regenerative Patch Technologies.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 5
- Study locations
NCT06557460 is a Phase 2 study of Geographic Atrophy and Dry Age-Related Macular Degeneration that is actively recruiting participants, run by Regenerative Patch Technologies. The registered enrollment target is 24 participants, below the 221-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT06557460, a Phase 2 study of Geographic Atrophy and Dry Age-Related Macular Degeneration, is actively recruiting participants, sponsored by Regenerative Patch Technologies.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea. Up to 6 surgical implantation sites will deliver the CPCB-RPE1 in this Phase IIb clinical trial. Additional study sites may serve as referral or follow-up sites. Twenty-four (24) subjects will participate in the trial and will be randomized 3:1 to one of 2 groups: * The treatment group receiving the CPCB-RPE1 implant (up to 18 subjects). * The control group receiving a simulated "sham" implantation procedure (up to 6 subjects)
Conditions Studied
Interventions
- DEVICE Surgical implantation of the CPCB-RPE1 implant
Study Locations (5)
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- Retina Associates of Southern California - Huntington Beach
- USC - Keck - Los Angeles
Illinois
- University Retina - Lemont
Texas
- Retina Consultants of Texas - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2040-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06557460
The ClinicalTrials.gov registry entry for NCT06557460 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (89% lower). The listed sponsor is Regenerative Patch Technologies, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Geographic Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Surgical implantation of the CPCB-RPE1 implant is the first listed.
NCT06557460 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT06557460 about?
NCT06557460 is a clinical study titled "A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)". This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea. Up to 6 surgical implantation sites will deliver the CPCB-RPE1 in this Phase IIb clinical trial. Add...
What is the current status of trial NCT06557460?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2025-08-01. Estimated completion is 2040-12.
What conditions does trial NCT06557460 study?
This clinical trial studies the following conditions: Geographic Atrophy, Dry Age-Related Macular Degeneration.
What interventions are being tested in trial NCT06557460?
The interventions under investigation include: Surgical implantation of the CPCB-RPE1 implant (DEVICE).
Who is sponsoring clinical trial NCT06557460?
This trial is sponsored by Regenerative Patch Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06557460 being conducted?
This trial has 5 study locations across California, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
RECRUITING · Phase 2
-
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.